Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects

Walker, Lauren M.; Tran, Susan H; Robinson, John W.

doi:10.1016/j.clgc.2013.05.004

Cited by 66 publications

(56 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These downregulated miRs have been shown to control genes that are involved in various physiologic functions in these tissues (Baltimore et al, 2008). Thus, overall, our miR data were consistent with DES-induced toxicity in reproductive organs and the ability to act as a carcinogen (Walker et al, 2013).…”

Section: Discussionsupporting

confidence: 71%

Exposure to Diethylstilbestrol during Pregnancy Modulates MicroRNA Expression Profile in Mothers and Fetuses Reflecting Oncogenic and Immunological Changes

et al. 2015

View full text Add to dashboard Cite

Prenatal exposure to diethylstilbestrol (DES) is known to cause an increased susceptibility to a wide array of clinical disorders in humans. Previous studies from our laboratory demonstrated that prenatal exposure to DES induces thymic atrophy and apoptosis in the thymus. In the current study, we investigated if such effects on the thymus result from alterations in the expression of microRNA (miR). To that end, pregnant C57BL/6 mice who were exposed to DES and miR profiles in thymocytes of both the mother and fetuses on postnatal day 3 (gestation day 17) were studied. Of the 609 mouse miRs examined, we noted 59 altered miRs that were common for both mothers and fetuses, whereas 107 altered miRs were specific to mothers only and 101 altered miRs were specific to fetuses only. Upon further analyses in the fetuses, we observed that DES-mediated changes in miR expression may regulate genes involved in important functions, such as apoptosis, autophagy, toxicity, and cancer. Of the miRs that showed decreased expression following DES treatment, miR-18b and miR-23a were found to possess complementary sequences and binding affinity for 39 untranslated regions of the Fas ligand (FasL) and Fas, respectively. Transfection studies confirmed that DES-mediated downregulation of miR-18b and miR-23a led to increased FasL and Fas expression. These data demonstrated that prenatal DES exposure can cause alterations in miRs, leading to changes in the gene expression, specifically, miR-mediated increased expression in FasL and Fas causing apoptosis and thymic atrophy.

show abstract

Section: Discussionsupporting

confidence: 71%

Exposure to Diethylstilbestrol during Pregnancy Modulates MicroRNA Expression Profile in Mothers and Fetuses Reflecting Oncogenic and Immunological Changes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…ED develops more slowly after radiation treatments, but still occurs in the majority of men within a few years of treatment (White et al, 2015). ADT, used either to enhance the efficiency of radiotherapy or as a systemic therapy in the case of advanced disease, produces not only ED but also reduces sexual desire (Walker et al, 2013), leading to delayed orgasm or anorgasmia Schover, 2015).…”

Section: Introductionmentioning

confidence: 99%

Men's Sexual and Relational Adaptations to Erectile Dysfunction After Prostate Cancer Treatment

Wassersug

Westle

Dowsett

2016

International Journal of Sexual Health

View full text Add to dashboard Cite

This study investigated how men adapt to erectile dysfunction and other sexual side-effects of prostate cancer treatment. The study recruited nonheterosexual and heterosexual men using an anonymous, international, online survey (N D 558). This article focuses on a qualitative analysis of answers (n D 348) to one open-ended question on sexual practices after treatment. Five themes emerged: (a) recovery of erectile function; (b) reframing sexual practices; (c) the importance of partners; (d) exploring anal sex; (e) the use of masturbation. The findings suggest that men should explore varied sexual options. Partners are also important in the overall recovery of men's sexual lives.

show abstract

“…Hot flashes are one of the most bothersome side effects of ADT, affecting up to 80% of men on this treatment 3. Almost 30% of patients consider hot flashes the most distressing side effect of ADT and more frequent or severe hot flashes are associated with greater distress.…”

Section: Side Effectsmentioning

confidence: 99%

“…Almost 30% of patients consider hot flashes the most distressing side effect of ADT and more frequent or severe hot flashes are associated with greater distress. Approximately half of patients still experience hot flashes even after 5 years of ADT 3. Low testosterone levels interrupt the negative feedback mechanism in hypothalamic noradrenaline production and reset the hypothalamic thermoregulatory center which results in vasomotor flushing.…”

Section: Side Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes

Ahmadi

Daneshmand

2014

PROM

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) constitutes the first-line treatment for patients with locally advanced tumors, recurrent or metastatic disease. Given its widespread use, clinicians should be familiar with common side effects of this treatment. This review focuses on common side effects of ADT and available treatment options to control the side effects. Also, it briefly compares continuous ADT with other therapeutic approaches for androgen deprivation in prostate cancer patients. Similar to hormonal medications, newer non-hormonal therapeutic options including gabapentin and acupuncture have at best moderate effect in controlling hot flashes in patients on ADT. Supervised and/or home exercise programs significantly improve ADT-related fatigue, metabolic/cardiovascular side effects, and cognitive dysfunction. Denosumab, a human monoclonal antibody against RANK-L, is more effective than bisphosphonates in preventing skeletal-related events in patients with metastatic or castrate-resistant prostate cancer and unlike bisphosphonates, it can also reduce the risk of vertebral fractures in men receiving ADT for non-metastatic prostate cancer. Toremifene, a selective estrogen receptor inhibitor, has dual beneficial effects on ADT-related osteoporosis and metabolic dysfunction. Metformin coupled with lifestyle modification is also a well-tolerated treatment for metabolic changes during ADT. While producing similar oncological outcomes, intermittent ADT is associated with higher quality of life in patients under ADT by improving bone health, less metabolic and hematologic complications, and fewer hot flashes and sexual dysfunction events.

show abstract

Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects

Cited by 66 publications

References 115 publications

Exposure to Diethylstilbestrol during Pregnancy Modulates MicroRNA Expression Profile in Mothers and Fetuses Reflecting Oncogenic and Immunological Changes

Exposure to Diethylstilbestrol during Pregnancy Modulates MicroRNA Expression Profile in Mothers and Fetuses Reflecting Oncogenic and Immunological Changes

Men's Sexual and Relational Adaptations to Erectile Dysfunction After Prostate Cancer Treatment

Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes

Contact Info

Product

Resources

About